HLX and cancer: The GSEA showed that 138 pathways were prominently activated, such as the PI3K-Akt signaling pathway, Rap1 signaling pathway, pathways in cancer, JAK-STAT signaling pathway, and toll-like receptor signaling pathway (Figures 5(a)–5(e)), and 8 pathways were inhibited in the HLX high expression group compared to the HLX low expression group (Table S2).